Black Diamond Therapeutics

Black Diamond Therapeutics is a precision oncology company pioneering the discovery and development of tumor-agnostic small molecule therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers that currently do not have any effective targeted treatment options. The foundation of the company is built upon a deep understanding of cancer genetics, protein structure and function as well as medicinal chemistry. The company’s proprietary technology platform MAP (Mutation, Allostery, Pharmacology) is designed to allow the company to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families having similar protein structures and develop a single small molecule therapy in a tumor-agnostic manner that targets the specific family of mutations. The cornerstone of their approach derives from evolving trends in targeted oncology therapies. Genetic sequencing of cancers has become increasingly widespread, leading to the discovery of multiple genetic alterations which were previously unaddressed, unsuccessfully targeted or overlooked. The approach offers a substantial opportunity to expand the number of cancer patients who could benefit from precision oncology medicines. The lead candidate BDTX-189 is designed to block the function of undrugged oncogenic mutations within the HER protein family, which occur across a range of tumor types.